Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Clinical Trial to Evaluate the Potential of T-COVID to Prevent Clinical Worsening in Patients with Early COVID-19

Next Previous
Trial Profile

A Phase 1/2 Clinical Trial to Evaluate the Potential of T-COVID to Prevent Clinical Worsening in Patients with Early COVID-19

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 25 Feb 2021 According to an Altimmune media release, data from this study is expected in Q2 2021.
  • 25 Feb 2021 According to an Altimmune media release, the company has completed the two safety cohorts. The trial is being overseen by an independent Data Safety Monitoring Committee, and no significant safety findings have been observed to date.
  • 09 Nov 2020 According to an Altimmune media release, based on the current rate of enrollment, the company anticipates a data read-out from this study in Q1 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top